Trial Profile
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Daprodustat (Primary)
- Indications Ischaemia; Myocardial ischaemia; Perioperative ischaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Apr 2016 According to an abstract presented at the 68th Annual Meeting of the American Academy of Neurology, this study planned to enroll 160 patients but halted early due to more serious adverse events.
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.